Recombinant viral vaccines for cancer

Trends in Molecular Medicine

Volumn 18, Issue 9, 2012, Pages 564-574

  Cawood, Ryan ^a   Hills, Thomas ^a   Wong, Suet Ling ^a   Alamoudi, Aliaa A ^a   Beadle, Storm ^a   Fisher, Kerry D ^a   Seymour, Leonard W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cancer immunity; Cancer vaccination; Cancer vaccines; Genetic vaccines; Recombinant viruses; Tumour microenvironment; Tumour associated antigens

Indexed keywords

ADENOVIRUS 5 D24 GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ALPHA INTERFERON; ALVAC CEA B7.1; CANCER VACCINE; CG 0070; CISPLATIN; CYTOKINE; FALIMAREV; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HSVM 002; INACTIVATED VIRUS VACCINE; INTERLEUKIN 2; JX 594; JX 795; JX 963; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MUCIN 1; NILUTAMIDE; NV 1042; ONCOLYTIC VIRUS; R 8306; R 8308; RECOMBINANT FOWLPOX VIRUS PROSTATE SPECIFIC ANTIGEN; RECOMBINANT VIRAL VACCINE; SUNITINIB; TALIMOGENE LAHERPAREPVEC; TG 1031; TG 4010; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VACCINE; VIRUS VECTOR; ZD 55;

ADVANCED CANCER; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; GENETIC ENGINEERING; GLIOMA; HEAD AND NECK CANCER; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INOPERABLE CANCER; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CANCER; LIVER TUMOR; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; METASTATIC MELANOMA; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TECHNOLOGY; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VIRUS PARTICLE;

ANIMALS; CANCER VACCINES; DNA VIRUSES; HUMANS; NEOPLASMS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84865608339     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.07.007     Document Type: Review

References (85)

1. Schreiber R.D., et al. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
2. Vesely M.D., et al. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29:235-271.
3. Francis D.P. Successes and failures: worldwide vaccine development and application. Biologicals 2010, 38:523-528.
4. Rollier C.S., et al. Viral vectors as vaccine platforms: deployment in sight. Curr. Opin. Immunol. 2011, 23:377-382.
5. Zhai Y.F., et al. Antigen-specific tumor vaccines - development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 1996, 156:700-710.
6. Rosenberg S.A., et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 1998, 90:1894-1900.
7. Lubaroff D.M., et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin. Cancer Res. 2009, 15:7375-7380.
8. Yu Q., et al. Poxvirus tropism for primary human leukocytes and hematopoietic cells. Methods Mol. Biol. 2009, 515:309-328.
9. Tsang K.Y., et al. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 1995, 87:982-990.
10. Conry R.M., et al. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin. Cancer Res. 2000, 6:34-41.
11. + T cell dependent and antibody mediated. Cancer Immunol. Immunother. 2006, 55:1081-1090.
12. Harrop R., et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin. Cancer Res. 2006, 12:3416-3424.
13. Amato R.J., et al. Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) - a phase 2 trial. J. Immunother. 2008, 31:577-585.
14. Amato R.J., et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha). A Phase 2 Trial. J. Immunother. 2009, 32:765-772.
15. Hawkins R.E., et al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J. Immunother. 2009, 32:424-429.
16. Amato R.J., et al. Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled phase III study. Clin. Cancer Res. 2010, 16:5539-5547.
17. Sheehy S.H., et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 2012, 7:e31208.
18. Horig H., et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. 2000, 49:504-514.
19. Arlen P.M., et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J. Urol. 2005, 174:539-546.
20. Zajac P., et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther. 2003, 14:1497-1510.
21. Adamina M., et al. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Mol. Ther. 2010, 18:651-659.
22. Hodge J.W., et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999, 59:5800-5807.
23. Aarts W.M., et al. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. 2002, 62:5770-5777.
24. Kantoff P.W., et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2010, 28:1099-1105.
25. Gulley J.L., et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 2010, 59:663-674.
26. Schuetz T., et al. Extended survival in second-line pancreatic cancer after therapeutic vaccination. J. Clin. Oncol. 2005, 23:2576.
27. Gulley J.L., et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 2008, 14:3060-3069.
28. Mohebtash M., et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 2011, 17:7164-7173.
29. Ramlau R., et al. A phase II study of Tg4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J. Thorac. Oncol. 2008, 3:735-744.
30. Scholl S.M., et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 2000, 23:570-580.
31. Oudard S., et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol. Immunother. 2011, 60:261-271.
32. Dreicer R., et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest. New Drugs 2009, 27:379-386.
33. Quoix E., et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011, 12:1125-1133.
34. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J. Natl. Cancer Inst. 2012, 104:599-613.
35. Mellor A.L., Munn D.H. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol. 2008, 8:74-80.
36. Kaufman H.L., et al. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum. Gene Ther. 2006, 17:239-244.
37. Heery C.P., et al. Intraprostatic vaccine administration in patients with locally recurrent prostate cancer. J. Clin. Oncol. 2011, 29(Suppl. 7). abstract 141.
38. Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 2007, 18:546-556.
39. Galanis E., et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010, 70:875.
40. Kaur B., et al. 'Buy one get one free': armed viruses for the treatment of cancer cells and their microenvironment. Curr. Gene Ther. 2009, 9:341-355.
41. Melcher A., et al. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol. Ther. 2011, 19:1008-1016.
42. Shi Y., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 2006, 16:126-133.
43. Parmiani G., et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 2007, 18:226-232.
44. Park B.H., et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008, 9:533-542.
45. Hwang T.H., et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol. Ther. 2011, 19:1913-1922.
46. Hernandez-Alcoceba R. Recent advances in oncolytic virus design. Clin. Transl. Oncol. 2011, 13:229-239.
47. Senzer N.N., et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 2009, 27:5763-5771.
48. Kaufman H.L., et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 2010, 17:718-730.
49. Cerullo V., et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010, 70:4297.
50. Pesonen S., et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int. J. Cancer 2012, 130:1937-1947.
51. Stewart T.J., Smyth M.J. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev. 2011, 30:125-140.
52. Lesterhuis W.J., et al. Cancer immunotherapy - revisited. Nat. Rev. Drug Discov. 2011, 10:591-600.
53. Madan R.A., et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012, 15:501-508.
54. Thorne S.H., et al. Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol. Ther. 2010, 18:1698-1705.
55. Li Yang Y.P., Moses Harold L. TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010, 31:220-227.
56. Miyazono H.I.a.K. TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer 2010, 10:415-424.
57. + T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-monoclonal antibody. Clin. Cancer Res. 2009, 15:6560-6569.
58. Ueda R., et al. Systemic inhibition of transforming growth factor in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin. Cancer Res. 2009, 15:6551-6559.
59. Seth P., et al. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor receptor II and human immunoglobulin Fc for breast cancer therapy. Hum. Gene Ther. 2006, 17:1152-1161.
60. Hu Z., et al. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor receptor Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum. Gene Ther. 2010, 21:1623.
61. Godkin, A. (2011) TaCTiCC (TroVax® And Cyclophosphamide Treatment In Colorectal Cancer). A pilot study to assess the effect of regulatory T cell depletion on 5T4-containing MVA (TROVAX®) vaccination in patients with INOPERABLE metastatic colorectal cancer. http://www.controlled-trials.com/ISRCTN54669986.
62. Park B.-H., et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008, 9:533-542.
63. Hwang T.-H., et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol. Ther. 2011, 10:1913-1922.
64. Breitbach C.J., et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477:99-102.
65. Lee J.H., et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 2010, 17:73-79.
66. Hu J.C.C., et al. A phase I study of OncoVEX(GM-CSF), a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 2006, 12:6737-6747.
67. Harrington K.J., et al. Phase I/II study of oncolytic HSV(GM-CSF) in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 2010, 16:4005-4015.
68. Cerullo V., et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010, 70:4297-4309.
69. Pesonen S., et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int. J. Cancer 2011, 130:1937-1947.
70. McKiernan J.M., et al. Phase 1 study of multi-dose administration of intravesical CG0070 in patients with non-muscle invasive bladder cancer (NMIBC). J. Urol. 2008, 179:616.
71. Grote D., et al. Neutrophils contribute to the measles virus-induced antitumor effect: Enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res. 2003, 63:6463-6468.
72. Varghese S., et al. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 2006, 13:253-265.
73. Parker J.N., et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:2208-2213.
74. Bortolanza S., et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in syrian hamsters. Mol. Ther. 2009, 17:614-622.
75. Shin E.J., et al. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 2007, 117:210-214.
76. Shashkova E.V., et al. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol. Ther. 2007, 15:598-607.
77. Kirn D.H., et al. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 2007, 4:2001-2012.
78. Zhao L., et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther. 2006, 13:1011-1022.
79. Greco A., et al. eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol. Ther. 2010, 18:295-306.
80. Kaliberova L.N., et al. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther. 2009, 16:794-805.
81. Andreansky S., et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998, 5:121.
82. Terada K., et al. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther. 2006, 13:705-714.
83. Cherry T., et al. Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy. Gene Ther. 2010, 17:1430-1441.
84. Fernandez M., et al. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 2002, 76:895-904.
85. Ino Y., et al. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin. Cancer Res. 2006, 12:643-652.